Recruitment
tumour
TUMOUR, PROSTATE CANCER
Patients will be identified at multidisciplinary uro-oncology tumour boards, at the time of confirmed PSMA-positive prostate cancer, staged N1M0, and referred for EBRT and ADT. When patients accept EBRT and ADT, they are subsequently informed about this study. Patients will receive oral and written information from their treating physician, and will be given at least 72 h to consider participation in the study. Patients who agree to participate will sign the informed consent form. Patients who decline participation will receive standard of care treatment (EBRT and ADT).